Phase I Safety and Tolerability Study of Birinapant in Chronic Hepatitis B
Status:
Terminated
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
This study evaluates the addition of birinapant in subjects with chronic Hepatitis B who are
currently receiving anti-viral therapy with either tenofovir or entecavir. Patients will
receive either birinapant or placebo in addition to their anti-viral therapy.